➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Merck
Boehringer Ingelheim
Johnson and Johnson
Moodys

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,372,995

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,372,995 protect, and when does it expire?

Patent 8,372,995 protects TYGACIL and is included in one NDA.

This patent has thirty-one patent family members in twenty-eight countries.

Summary for Patent: 8,372,995
Title:Crystalline solid forms of tigecycline and methods of preparing same
Abstract: Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.
Inventor(s): Krishnan; Lalitha (Suffern, NY), Deshmukh; Subodh S. (White Plains, NY), Hadfield; Anthony (St. Petersburg, FL), Huang; W. James (Hillsborough, NJ), Ku; Mannching Sherry (Thiells, NY)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:11/440,032
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,372,995
Patent Claim Types:
see list of patent claims
Composition; Process;

Drugs Protected by US Patent 8,372,995

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Baxter
Boehringer Ingelheim
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.